Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, its adoption is restricted by a complicated dosing protocol that necessitates administration while fasting with water, as well as the avoidance of food or medications for a minimum of 30 min afterward. Such requirements reduce convenience and compromise adherence in routine practice [11, 16].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [16]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Pharmacologically, long-acting GLP-1 receptor agonists (GLP-1RAs) exhibit glucoregulatory functions via a triumvirate of mechanisms, namely, stimulation of insulin release in a glucose-dependent manner, suppression of glucagon activity during hyperglycemia, and a minor delay of gastric emptying resulting in slower glu…”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“In line with this, recent advancements in fatty acid acylation– based protraction technology have provided the possibility of achieving extended plasma half-lives (t1⁄2) without increasing molecular size, leading to the discovery of semaglutide, a GLP-1 analog with a t1⁄2 of ~1 week in humans (8).”
BackgroundSelf-citationThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Self-citationIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationpH stability and activity curves of pepsin with special reference to their clinical importance.
Piper, D. W., & Fenton, B. H. (1965) · Gut · doi:10.1136/gut.6.5.506 · Cited by 385
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Aguirre, T. A. S., Teijeiro-Osorio, D., Rosa, M., Coulter, I. S., Alonso, M. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.004 · Cited by 299
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Wang, J., Yadav, V., Smart, A. L., Tajiri, S., & Basit, A. W. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500809f · Cited by 245
Rapid epithelial restitution of the rat gastric mucosa after ethanol injury.
Lacy, E. R., & Ito, S. (1984) · PubMed · Cited by 204
Gastric transit and small intestinal transit time and motility assessed by a magnet tracking system
Worsøe, J., Fynne, L., Gregersen, T., Schlageter, V., Christensen, L. A., Dahlerup, J. F., Rijkhoff, N. J., Laurberg, S., & Krogh, K. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-145 · Cited by 178
Classifying Surfactants with Respect to Their Effect on Lipid Membrane Order
Nazari, M., Kurdi, M., & Heerklotz, H. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2011.12.029 · Cited by 169
Absorption-Enhancing Mechanism of EDTA, Caprate, and Decanoylcarnitine in Caco-2 Cells
Tomita, M., Hayashi, M., & Awazu, S. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js9504604 · Cited by 169
Wettergren, A., Wøjdemann, M., Meisner, S., Stadil, F., & Holst, J. J. (1997) · Gut · doi:10.1136/gut.40.5.597 · Cited by 153
Tuvia, S., Pelled, D., Marom, K., Salama, P., Levin-Arama, M., Karmeli, I., Idelson, G. H., Landau, I., & Mamluk, R. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1303-9 · Cited by 140
Weitschies, W., Blume, H. H., & Mönnikes, H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.07.007 · Cited by 138
Oral delivery of macromolecules using intestinal patches: applications for insulin delivery
Whitehead, K. A., Shen, Z., & Mitragotri, S. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.04.013 · Cited by 129
Regional intestinal drug permeation: Biopharmaceutics and drug development
Lennernäs, H. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.025 · Cited by 103
The dynamic gastric environment and its impact on drug and formulation behaviour
Van Den Abeele, J., Rubbens, J., Brouwers, J., & Augustijns, P. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.08.060 · Cited by 102
Oral Delivery of Insulin with the eligen(®) Technology: Mechanistic Studies
Malkov, D., Angelo, R., Wang, H.-Z., Flanders, E., Tang, H., & Gomez-Orellana, I. (2005) · Current Drug Delivery · doi:10.2174/1567201053586001 · Cited by 98
Rapid repair of injured gastric mucosa.
Ito, S., Lacy, E. R., Rutten, M. J., Critchlow, J. F., & Silen, W. (1984) · PubMed · Cited by 95
Brayden, D. J., Gleeson, J. P., & Walsh, E. G. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.10.008 · Cited by 88
Effect of pH on Bile Salt Injury to Mouse Gastric Mucosa
Eastwood, G. L. (1975) · Gastroenterology · doi:10.1016/s0016-5085(75)80132-6 · Cited by 88
Welling, S. H., Hubálek, F., Jacobsen, J. B., Brayden, D. J., Rahbek, U. L., & Buckley, S. T. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.12.017 · Cited by 86
Self-citationCooke, C. E., Lee, H. Y., Tong, Y. P., & Haines, S. T. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903421994 · Cited by 78
Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations
Frederiksen, T. M., Sønderby, P., Ryberg, L. A., Harris, P., Bukrinski, J. T., Scharff‐Poulsen, A. M., Elf-Lind, M. N., & Peters, G. H. J. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2015.07.051 · Cited by 72
Acylated non-α-amino acids as novel agents for the oral delivery of heparin sodium, USP
Leone‐Bay, A., Paton, D. R., Variano, B., Leipold, H., Rivera, T., Miura-Fraboni, J., Baughman, R. A., & Santiago, N. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00101-6 · Cited by 64
Karsdal, M. A., Byrjalsen, I., Riis, B. J., & Christiansen, C. (2008) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-8-5 · Cited by 63
Wang, X., Maher, S., & Brayden, D. J. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.5 · Cited by 52
Transcellular and Lipophilic Complex-Enhanced Intestinal Absorption of Human Growth Hormone
Wu, S.-J., & Robinson, J. R. (1999) · Pharmaceutical Research · doi:10.1023/a:1014809916407 · Cited by 47
Trier, S., Linderoth, L., Bjerregaard, S., Andresen, T. L., & Rahbek, U. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109939 · Cited by 43
Self-citationInfluence of food intake on the bioavailability and efficacy of oral calcitonin
Karsdal, M. A., Byrjalsen, I., Azria, M., Arnold, M., Choi, L., Riis, B. J., & Christiansen, C. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03371.x · Cited by 38
Rapid Repair of the Surface Epithelium in Human Gastric Mucosa After Acute Superficial Injury
Lacy, E. R., Morris, G. P., & Cohen, M. M. (1993) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199312001-00023 · Cited by 29
Lee, Y.-H., Perry, B. A., Sutyak, J. P., Stern, W., & Sinko, P. J. (2000) · Pharmaceutical Research · doi:10.1023/a:1007596821702 · Cited by 24
McIntyre, C., Schmidt, J., Castelli, M., & Bittner, B. (2011) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(11)50084-x · Cited by 14
Drug-drug interaction study between a novel oral ibandronate formulation and metformin
Bittner, B., Mclntyre, C., Jordan, P., & Schmidt, J. (2012) · Arzneimittelforschung · doi:10.1055/s-0031-1300591 · Cited by 5
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationAdvances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Metadata
- Authors
- Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., Pedersen, B. L., Skyggebjerg, R. B., Benie, A. J., Strauss, H. M., Wahlund, P.-O., Bjerregaard, S., Farkas, E., Fekete, C., Søndergaard, F. L., Borregaard, J., Hartoft-Nielsen, M.-L., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S, 2760 Måløv, Denmark.
- HUN-REN Institute of Experimental Medicine (HU)
- Tufts Medical Center (US)
- Novo Nordisk A/S, 2860 Søborg, Denmark.
- Corresponding author
- Buckley, Stephen T.
- Bækdal, Tine A.
- Vegge, Andreas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-14
- Volume
- 10
- Issue
- 467
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2901306081
- Cited by
- 553
- References
- 40
- Citations by year
- 2026: 84 · 2025: 89 · 2024: 74 · 2023: 53 · 2022: 73 · 2021: 77 · 2020: 69 · 2019: 32 · 2018: 1
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, GLP-1 receptor agonists, SNAC, gastric absorption, oral drug delivery, tablet formulation, tight junctions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adolescent, Adult, Aged, Animals, Cell Membrane, Dogs, Glucagon-Like Peptides, Epithelial Cells, Gastric Mucosa, Humans, Hydrogen-Ion Concentration, Intestinal Absorption, Male, Middle Aged, Stomach, Time Factors, Rats, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.